Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden, July 2021 to January 2022-Reference-Cited by-同舟云学术

Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden, July 2021 to January 2022

Published:2022-03-03 Issue:9 Volume:27 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Kahn Fredrik¹^ORCID,Bonander Carl²^ORCID,Moghaddassi Mahnaz³^ORCID,Rasmussen Magnus¹^ORCID,Malmqvist Ulf⁴,Inghammar Malin¹^ORCID,Björk Jonas⁵⁴^ORCID

Affiliation:

1. Department of Clinical Sciences Lund, Section for Infection Medicine, Skåne University Hospital, Lund University, Lund, Sweden

2. School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

3. Social Medicine and Global Health, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden

4. Clinical Studies Sweden, Forum South, Skåne University Hospital, Lund, Sweden

5. Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden

Abstract

We compared the risk of severe COVID-19 during two periods 2021 and 2022 when Delta and Omicron, respectively, were the dominating virus variants in Scania county, Sweden. We adjusted for differences in sex, age, comorbidities, prior infection and vaccination. Risk of severe disease from Omicron was markedly lower among vaccinated cases. It was also lower among the unvaccinated but remained high (> 5%) for older people and middle-aged men with two or more comorbidities. Efforts to increase vaccination uptake should continue.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference10 articles.

1. SARS-CoV-2 Omicron VOC transmission in Danish households.;Lyngse;medRxiv,2021

2. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al. Effectiveness of COVID-19 vaccines against Omicron or Delta infection. medRxiv. 2022:2021.12.30.21268565. https://doi.org/10.1101/2021.12.30.21268565

3. Ulloa AC, Buchan SA, Daneman N, Brown KA. Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study, Ontario, Canada. medRxiv. 2021:2021.12.24.21268382. https://doi.org/10.1101/2021.12.24.21268382

4. Reduced risk of hospitalisation associated with infection with SARS-CoV-2 Omicron relative to Delta: a Danish cohort study.;Bager;SSRN,2022

5. Ferguson N, Ghani A, Hinsley W, Volz E. Report 50 - Hospitalisation risk for Omicron cases in England. London: Imperial College; 2021. Available from: https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-50-severity-omicron

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Laboratory Diagnostics Accuracy for COVID-19 versus Post-COVID-19 Syndrome in Lung Disease Patients with Multimorbidity;Journal of Personalized Medicine;2024-01-31

2. The relative effectiveness of three and four doses of COVID-19 vaccine in Victoria, Australia: A data linkage study;Vaccine;2024-01

3. Timing of hepatectomy following the Omicron variant infection for vaccinated-patients: A retrospective cohort study;Hepatobiliary & Pancreatic Diseases International;2024-01

4. Effect of Mutational Difference on Systemic Immune Inflammation Index in Patients with a Diagnosis of COVID-19;Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy;2023-12-28

5. Waning protection after vaccination and prior infection against COVID-19-related mortality over 18 months;Clinical Microbiology and Infection;2023-12